Research · Sep 3, 2026
[ESAB] ESAB Corporation Thesis 2026: Recurring Welding Consumables and a Lean Operating System Drive Margins Higher
ESAB Corporation (NYSE: ESAB) is a North Bethesda, Maryland-headquartered global leader in fabrication technology — welding and cutting equipment and consumables — and gas-control equipment. ESAB ('Elektriska Svetsnings-Aktiebolaget') is one of the oldest names in welding, founded in Sweden in 1904 by the inventor of the coated welding electrode; it became part of Charter International, then of Colfax Corporation (which bought Charter in 2012), and in April 2022 Colfax split into two public companies — Enovis (the medical-technology business) and ESAB Corporation (this entity, the fabrication-technology and gas-control business) — spinning ESAB off as a standalone with Shyam Kambeyanda as President & CEO. ESAB reports two segments by geography — Americas and EMEA & APAC — and within each sells three product groups: Equipment (welding power sources, wire feeders, plasma and oxy-fuel cutting systems, robotic/automated welding cells, digital welding-management software), Consumables (filler metals — solid and flux-cored welding wire, stick electrodes, fluxes, brazing alloys — the recurring, high-margin core, roughly half-ish of revenue) and Gas Control (pressure regulators, flowmeters, manifolds, cutting and welding gas apparatus, and a growing specialty- and medical-gas-equipment line, marketed largely under the GCE Group brand); end-markets span general fabrication, construction and infrastructure, energy (oil & gas, pipelines, power, wind), transportation, shipbuilding, repair & maintenance, and healthcare (medical gas); geography is genuinely global with a large share of revenue from emerging markets (Latin America, the Middle East, India, Asia, Eastern Europe — a structural growth tailwind but a source of currency and macro volatility). ESAB enters FY2026 with FY2025 revenue selected various aggregate ~$2.6-2.95B, aggregate adjusted EPS ~$5.00-6.25 (GAAP lower on acquired-intangible amortization) and adjusted EBITDA ~$490-570M (~18-20%+ margin, expanding). The first thesis pillar is Welding & Cutting (Equipment plus Consumables) — the heart of ESAB, the large majority of revenue, with two complementary halves: Equipment is the capital-goods half (arc-welding power sources — MIG/MAG, TIG, stick, submerged-arc — wire feeders and torches, plasma and oxy-fuel cutting machines, robotic and automated welding systems, digital tools — sold to fabricators, OEMs and contractors — the more cyclical, project- and capex-linked piece, with growth from the automation/digitalization trend as skilled-welder shortages push customers toward automated cells, plus product refresh); Consumables is the razor-blade half and the prize (filler metals — solid and flux-cored welding wire, covered electrodes, submerged-arc wire and fluxes, hardfacing alloys, brazing/soldering products — consumed every time something is welded, producing a recurring revenue stream roughly half-ish of total company revenue with attractive margins, especially in higher-spec/alloy-rich/branded segments, and demand tied to the intensity of fabrication activity rather than capex decisions — more resilient than equipment); the two reinforce each other (an installed base of ESAB equipment pulls through ESAB consumables; a strong consumables brand supports equipment placement); FY2025 dynamics are solid consumables demand in most regions (emerging-market fabrication a tailwind; developed-market general industry mixed), equipment demand tracking the industrial-capex cycle (some softness in spots), pricing actions offsetting raw-material (steel, alloy) and labor inflation, favorable mix toward higher-value products, and EBX-driven cost-outs lifting margins; FY2026 catalyst is global fabrication and construction/infrastructure activity (energy-transition projects — wind, pipelines, LNG, grid — plus reshoring/infrastructure spend), emerging-market growth, pricing/cost spread, the automation/digitalization product cycle, and new-product launches; risks/competitors are a global industrial downturn (hits both halves, equipment harder), raw-material cost spikes outrunning pricing, currency (a large non-USD revenue base), and a competitive field — Lincoln Electric (LECO, the closest comp, US-centric), Illinois Tool Works' welding segment (ITW — Miller Electric / Hobart brands), voestalpine Böhler Welding, Fronius (private), Kemppi (private), regional welding-product makers, and Hypertherm (private) in plasma cutting. The second pillar combines Gas Control (the diversification engine), EBX (the margin engine) and bolt-on M&A (the growth lever): Gas Control — marketed largely under the GCE Group brand — makes the equipment that controls and delivers industrial and specialty gases (pressure regulators, flowmeters, manifolds and gas-distribution systems, cutting and welding torches and gas apparatus, and high-purity/specialty-gas equipment), and ESAB has deliberately expanded it from a welding-adjacent gas-apparatus business into a broader specialty- and medical-gas-equipment platform through acquisitions (Ohio Medical — medical suction and oxygen therapy/regulators; Therapy Equipment; Sager S.A. and similar medical-gas businesses; plus welding-automation tuck-ins like SUMIG) — adding faster-growing, less-cyclical, higher-margin healthcare-adjacent revenue (hospital gas systems, oxygen therapy, medical regulators) that diversifies away from pure industrial fabrication; EBX ('ESAB Business Excellence') is the company's lean-operating system — a direct descendant of the Colfax Business System (itself in the Danaher Business System tradition) — a continuous-improvement discipline (kaizen, value-stream mapping, 80/20 simplification, footprint rationalization, procurement, pricing rigor) that ESAB has used since the spin to drive structural margin expansion (adjusted EBITDA margin has climbed steadily, with management targeting further gains toward the low-20s%+) — the core of the equity story alongside the consumables annuity; M&A — ESAB runs a disciplined bolt-on acquisition program (specialty/medical gas, welding automation, geographic/product fill-ins), funded by free cash flow and modest debt, integrated via EBX; FY2025 dynamics are Gas Control growing (medical/specialty gas the faster piece), EBX delivering ongoing margin gains, several bolt-ons completed and integrated, and leverage coming down; FY2026 catalyst is Gas Control / medical-gas growth, EBX-driven margin progression (toward the company's targets), bolt-on M&A cadence and accretion, and the de-leveraging path freeing up capital for more deals/buybacks; risks/competitors are medical-gas integration and regulatory (FDA/quality) risk on the healthcare-adjacent businesses, the limits of EBX (margin gains get harder at the margin), overpaying for or mis-integrating acquisitions, and competition in gas control from Air Liquide / Linde (LIN) (captive gas-equipment), Rotarex, Cavagna, and medical-gas players Amico, Precision Medical, BeaconMedaes (Atlas Copco) and Drägerwerk. The capital story: a small dividend (selected various aggregate ~$0.30-0.40/share annually, ~0.1-0.3% yield — token, cash directed at de-leveraging and M&A), opportunistic buybacks (~60M shares, roughly flat-to-slightly-down), net debt selected various aggregate ~$0.6-1.2B (term loans, notes and a revolver — used at the spin to capitalize the company and since for acquisitions, paid down with strong FCF), ~1.0-2.5x net debt/EBITDA (down sharply since the 2022 spin), a near-investment-grade credit profile (BB+/Ba1-area, positive trajectory toward IG), ample liquidity, solid FCF conversion (high-margin consumables mix, modest capex — not capital-intensive), capital allocation of de-leveraging (the headline use post-spin) → bolt-on M&A → small dividend → buybacks, no material pension overhang, with the de-leveraging trajectory, the path to an investment-grade rating, currency translation of the large non-USD operations, and acquired-intangible amortization as balance-sheet considerations. At ~$95-150 per share on ~60M shares (~$5.5-9.0B equity, ~$6.5-10.5B EV) ESAB trades at selected various aggregate ~16-26x P/E, ~12-19x EV/EBITDA and ~16-26x EV/FCF with a token ~0.1-0.3% dividend yield — a multiple re-rated upward since the spin on EBX-driven margin expansion, de-leveraging and consistent execution (narrowing but not closing the discount to its closest comp) — versus Lincoln Electric (LECO, the direct read-through, the US-listed pure-play welding leader trading at a premium ESAB is working toward), Illinois Tool Works (ITW, a large welding segment — Miller/Hobart), Colfax's other spin-off Enovis (ENOV), the broader diversified-industrials/quality-compounder set Dover (DOV), Crane (CR), IDEX (IEX), Ingersoll Rand (IR), Roper (ROP) for the EBX/operating-system comparison, and Linde (LIN) and Air Liquide (captive) plus medical-gas-adjacent names on gas control. FY2026 base case is selected various aggregate ~$2.7-3.05B revenue + ~$5.50-6.75 adj. EPS + ~$510-590M adjusted EBITDA + ~1.0-2.5x net debt/EBITDA + continued EBX margin gains + bolt-on M&A + de-leveraging — steady mid-single-digit growth with margin expansion; bull case ~$2.9-3.3B+ revenue + ~$6.50-8.00+ adj. EPS on strong global fabrication demand (energy-transition and infrastructure projects, emerging-market growth), Gas Control/medical-gas acceleration, EBX pushing the adjusted EBITDA margin into the low-20s%+, accretive bolt-ons, reaching investment grade (lower funding cost), buybacks, and a continued re-rating toward LECO's multiple; bear case ~$2.4-2.7B revenue + ~$4.25-5.25 adj. EPS on a global industrial downturn (equipment demand falling, consumables volumes softening), a steel/alloy cost spike outrunning pricing, emerging-market currency hits, a stalled medical-gas integration, leverage rising on a debt-funded deal, and a multiple de-rating toward the cyclical-industrials average. The thesis depends on the Welding & Cutting pipeline (Equipment + the recurring high-margin Consumables core) plus the Gas Control + EBX + M&A pipeline (gas-equipment and medical-gas growth + the lean-operating-system margin expansion + disciplined bolt-ons) plus the consumables annuity plus a healthy global fabrication/industrial backdrop plus the de-leveraging path toward investment grade plus Shyam Kambeyanda's execution of the post-spin EBX playbook.